AOD-9604: The Fat Loss Peptide Fragment

Growth hormone's relationship with fat metabolism has been understood for decades. One of GH's primary effects is stimulating lipolysis — the breakdown of stored fat — through beta-3 adrenergic receptors in adipose tissue. The problem with using GH for this purpose is that it also raises blood glucose and insulin resistance, which creates complications particularly in people who already have metabolic issues.

AOD-9604 is an attempt to separate those effects. It's a modified fragment of the GH molecule — specifically the C-terminal fragment (amino acids 176–191) with an additional modification at one end — that retains the lipolytic activity without the metabolic downsides.

What the Research Shows

The early animal research on AOD-9604 was genuinely encouraging. Studies in obese rodents showed significant fat reduction with daily administration, without the effects on blood glucose or IGF-1 levels that you'd see with full growth hormone. The compound appeared to work specifically on adipose tissue through the beta-3 receptor pathway while leaving the growth-promoting and insulin-sensitising mechanisms of full GH essentially untouched.

Australian biotechnology company Metabolic Pharmaceuticals moved AOD-9604 into human clinical trials in the 2000s, which puts it in a different position to many research peptides — it has actual human trial data. The trials showed modest weight loss results, though not dramatic enough to justify continued commercial development as a pharmaceutical product. Phase 2 trials showed a statistically significant but clinically modest reduction in body weight compared to placebo. Phase 3 trials failed to meet their primary endpoints.

The compound was discontinued as a pharmaceutical development programme. The FDA did grant it Generally Recognised as Safe (GRAS) status for use as a food additive, which is worth noting — it's not a regulatory endorsement of its efficacy, but it does say something about the safety profile.

Why People Still Use It

The commercial failure of AOD-9604 as a pharmaceutical was partly a function of what drug companies need from a product — a large, statistically robust effect in a randomised controlled trial — rather than necessarily what individuals experience. The anecdotal reports from people using AOD-9604 as a research compound tend to be more positive than the clinical data, which is a pattern you see across this entire category.

Several factors might explain the gap. The clinical trials used a fixed dose across a diverse population; individual response to peptides varies considerably. The trial participants were not necessarily optimising the other variables — diet, training, timing — that people who use research compounds typically do. And the endpoints and timeframes of commercial drug trials are designed to demonstrate effects at a population level, which requires larger effect sizes than an individual might need to see a meaningful personal benefit.

The No-IGF-1 Advantage

The reason AOD-9604 continues to attract interest despite the clinical trial results is the theoretical clean profile. Compounds that raise IGF-1 — including full GH, ipamorelin, and CJC-1295 — require more careful monitoring because sustained IGF-1 elevation has theoretical implications for cell proliferation. AOD-9604 doesn't raise IGF-1 at all, which makes it attractive for people who want some of GH's fat metabolism effects without engaging that pathway.

It's also frequently considered in the context of stacking — using AOD-9604 alongside other compounds for its specific lipolytic action while using a separate protocol for recovery or body composition. The relative selectivity of its mechanism makes it theoretically compatible with a range of other compounds without significant interaction concerns.

Dosing and Administration

Research protocols typically use doses of 300–500mcg per day, administered subcutaneously. Morning injection on an empty stomach is the standard approach, reflecting the logic that the fasted state maximises lipolytic activity. Some people split the dose morning and evening.

Cycle lengths are typically 8–16 weeks. The compound has a short half-life — around 30 minutes — which means daily injection rather than less frequent dosing.

Honest Expectations

AOD-9604 is not a dramatic fat loss compound. The clinical data and the anecdotal data both suggest modest effects — meaningful for some people, insufficient for others. It's not in the same category as semaglutide for weight loss magnitude. What it offers is a potentially clean mechanism with a good safety profile, which makes it an interesting adjunct rather than a standalone strategy.

Anyone expecting dramatic results from AOD-9604 alone will likely be disappointed. In the context of a solid diet and training programme, where marginal improvements compound over time, the picture may be different.